Investors put $400M into biotech licensing obesity drugs from China
Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed…
0 Comments
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate
San Francisco-based Bolt Biotherapeutics on Tuesday said it is ending development of its lead cancer…
0 Comments
Eisai sets new revenue target for Alzheimer’s drug Leqembi
One of the developers behind the Alzheimer’s disease drug Leqembi has set new revenue expectations…
0 Comments
FogPharma, Artbio join forces to design a different radiopharma drug
FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies…
0 Comments
Bayer details layoffs as company shake-up continues
German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year…
0 Comments
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
Listen to the article 3 min This audio is auto-generated. Please let us know if…
0 Comments
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
Takeda Pharmaceutical is betting potentially billions of dollars on drugs designed to slow Alzheimer’s disease…
0 Comments
Acknowledging comorbidities in trial design is essential for successful outcomes
Comorbidities are associated with a lack of representation in randomized controlled trials. As a result,…
0 Comments
Novo taps another Flagship startup in search for next obesity drugs
Novo Nordisk is again turning to a Flagship Pioneering startup to find new weight loss…
0 Comments
Novavax gets a lifeline with Sanofi vaccine pact
Dive Brief: Sanofi will pay vaccine maker Novavax $500 million and take a small equity…
0 Comments